One step nanosensor for single and multidrug resistance in acute coronary syndrome (ACS)
An embodiment relates to a method of detecting a drug resistance in a patient comprising adding nanoparticles to sample platelets to form activated platelets containing the nanoparticles and comparing a difference in activation of the activated platelets and the sample platelets. Another embodiment relates to a method of monitoring a thrombotic risk factor in a subject in a general population comprising adding nanoparticles to sample platelets to form activated platelets containing the nanoparticles and comparing a difference in activation of the activated platelets and the sample platelets. Yet another embodiment relates to a kit comprising nanoparticles, a fluorescence dye tagged antibody and optionally a buffer, wherein the kit is configured to detect a drug resistance in a patient or a likelihood of the thrombotic risk factor in a subject in general population.
1. A method for detecting resistance to antiplatelet drugs in a patient diagnosed with or at risk for acute coronary syndrome (ACS) comprising:
obtaining a platelet sample from the patient, wherein the patient is taking one or more antiplatelet drugs;
dividing the platelet sample into a first portion of platelets and a second portion of platelets;
contacting noble metal containing nanoparticles to the first portion of platelets;
contacting the first and second portion of platelets with a labeled anti-CD62P antibody;
measuring the expression of CD62P in the first portion of platelets;
measuring the expression of CD62P in the second portion of platelets; and
comparing the level of CD62P expression in the first portion of platelets to the level of CD62P expression in the second portion of platelets; and
determining the patient's resistance to antiplatelet drugs, wherein a substantially higher level of CD62P expression in the first portion of platelets indicates that the subject is not resistant to the antiplatelet drug.
2. The method of claim 1 , wherein a lack of a substantial difference in CD62P expression between the first portion of platelets and the second portion of platelets indicates a likelihood of drug resistance in the patient.
3. The method of claim 1 , wherein the labeled anti-CD62P antibody comprises a fluorescently labeled anti-CD62P antibody.
4. The method of claim 1 , wherein the method is configured to detect the antiplatelet drug resistance in the patient to a single or multiple drugs for ACS.
5. The method of claim 1 , wherein the nanoparticles comprise particles having particle sizes in a range of about 1 nm to about 100 nm, about 10 nm to about 50 nm, about 15 nm to about 25 nm, or about 18 nm to about 20 nm.
6. The method of claim 1 , wherein the drug resistance is to a drug comprising clopidogrel, aspirin or combinations thereof.
7. The method of claim 1 , wherein the noble metal nanoparticles comprise one or more metals selected from the group consisting of: rhodium, iridium, palladium, silver, osmium, platinum and gold.